(Automated Immunoassays)
(MSD-Multiplex ECLIA)
(SPR Biomarker Interactions)
(ImmunoCAP)
(Western Blot Imager)
(Immune Cell Cytokine Release)
(Low Volume Automated ELISA)
(Multiplex Immunoassay)
SAN DIEGO LAB
~34,000 sq. ft.
CRO
Immunoassay
Mass Spectrometry
USA HQ (DURHAM)
~265,000 sq. ft.
Discovery
Preclinical/clinal
Manufacturing
BOSTON LAB
~22,000 sq. ft.
Bioanalytical Services
Diagnostic Testing
EUROPEAN HQ (HAMBURG)
~2,900 m2 (31,000 sq. ft.)
Assay Development
Validation
Sample Analysis
Global Disease Studies
MELBOURNE LAB
2,777 Square Meters
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Virology
Immunology
FIH trials & early-phase clinical trials
Central laboratory services
BRISBANE LAB
1,566 Square Meters
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Virology
Immunology
FIH trials & early-phase clinical trials
Central laboratory services
Explore the capabilities of each platform in more detail to learn which option will be best for your unique study. Our team is available for specific guidance on platform selection.
On this episode of Molecular Moments, Jim McNally, Ph.D., speaks with Adam Stasio, president of SciMed, whose mission is to
Share This 
The third and final blog in our cell and gene therapy series will focus on PCR as a bioanalytical tool
Share This 
In this article, Chief Scientific Officer at BioAgilytix, Jim McNally, Ph.D., explores why bioanalysts should prepare for the impending wave
Share This 
Once the patent on a previously ground-breaking blockbuster molecule comes to an end, there is an opportunity for biosimilar versions
Share This 
A3P Biomedical AB, a Swedish company specialized in advanced prostate cancer diagnostics, and BioAgilytix, a global bioanalytical services provider, have
Share This 
BioAgilytix Commits to United Nations Global Compact Leading bioanalytical services provider pledges to act in support of human rights
Share This The third and final blog in our cell and gene therapy series will focus on PCR as a bioanalytical tool
Share This 
An Overview of Cell Therapy: As we continue our blog series on cell and gene therapy, we will now dive
Share This 
An Introduction to Gene Therapy: As early as the 1970’s, the term “gene therapy” was used for the treatment of
Share This 
(Automated Immunoassays)
(MSD-Multiplex ECLIA)
(SPR Biomarker Interactions)
(ImmunoCAP)
(Western Blot Imager)
(Immune Cell Cytokine Release)
(Low Volume Automated ELISA)
(Multiplex Immunoassay)
SAN DIEGO LAB
~34,000 sq. ft.
CRO
Immunoassay
Mass Spectrometry
USA HQ (DURHAM)
~265,000 sq. ft.
Discovery
Preclinical/clinal
Manufacturing
BOSTON LAB
~22,000 sq. ft.
Bioanalytical Services
Diagnostic Testing
EUROPEAN HQ (HAMBURG)
~2,900 m2 (31,000 sq. ft.)
Assay Development
Validation
Sample Analysis
Global Disease Studies
MELBOURNE LAB
2,777 Square Meters
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Virology
Immunology
FIH trials & early-phase clinical trials
Central laboratory services
BRISBANE LAB
1,566 Square Meters
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Virology
Immunology
FIH trials & early-phase clinical trials
Central laboratory services
Explore the capabilities of each platform in more detail to learn which option will be best for your unique study. Our team is available for specific guidance on platform selection.
On this episode of Molecular Moments, Jim McNally, Ph.D., speaks with Adam Stasio, president of SciMed, whose mission is to
Share This The third and final blog in our cell and gene therapy series will focus on PCR as a bioanalytical tool
Share This In this article, Chief Scientific Officer at BioAgilytix, Jim McNally, Ph.D., explores why bioanalysts should prepare for the impending wave
Share This Once the patent on a previously ground-breaking blockbuster molecule comes to an end, there is an opportunity for biosimilar versions
Share This A3P Biomedical AB, a Swedish company specialized in advanced prostate cancer diagnostics, and BioAgilytix, a global bioanalytical services provider, have
Share This BioAgilytix Commits to United Nations Global Compact Leading bioanalytical services provider pledges to act in support of human rights
Share This The third and final blog in our cell and gene therapy series will focus on PCR as a bioanalytical tool
Share This An Overview of Cell Therapy: As we continue our blog series on cell and gene therapy, we will now dive
Share This An Introduction to Gene Therapy: As early as the 1970’s, the term “gene therapy” was used for the treatment of
Share This
Unparalleled Partnership Through
Every Phase of Oncology Research
BioAgilytix is working alongside our pharma and biotech customers to help lead change in the way cancer is treated, looking beyond generic chemotherapies and toward new, more effective personalized approaches. As a bioanalytical CRO specialized in complex drug development efforts, including oncology and immune-oncology studies and trials, we deliver multi-stage bioanalytical services and the extensive expertise needed to add value every step of the way.
The clinical landscape for cancer is currently undergoing an exciting shift. Cancer treatment has historically consisted of surgery, chemotherapy, and radiotherapy, but new therapies have recently emerged as promising weapons in the fight against this terrible disease. For example, antibody drug conjugates (ADCs) use high specificity to bring a tumor-killing agent to its location to eliminate tumor cells only, leaving healthy tissue untouched. Additionally, immuno-oncological approaches are being developed which leverage patients’ own immune systems to eliminate cancer cells, and scientists and doctors are seeing real promise in such targeted therapies.
These molecular and possibly personalized approaches may lead to the dusk of generic chemotherapies and to a new level of curative cancer treatment – and possibly even to the eradication of most types of cancer. However, it takes veteran scientific expertise – and a deep understanding of methods such as mAbs, adoptive cell therapy, immune checkpoint therapy and more – in order to fully realize the potential of such complex biotherapeutics.
There are many extremely promising methods in the realm of immune oncological treatment; this blog post focuses on a few examples that demonstrate the immense power immuno-oncology holds.
From discovery through Phases I, II, II and IV, BioAgilytix offers comprehensive bioanalytical support for every stage of oncology drug research and development. We uphold the highest commitment to superior science, supporting our laboratory staff with a Quality team that has extensive experience in maintaining outstanding reliability in regulated environments.
As an industry leader in oncology-related bioanalytical services, we provide expert support in xenograft, PBMC, and tumor analysis, as well as for cancer-related cell-based assays.
The following services are regularly used in oncology-related studies at BioAgilytix:
To deliver our comprehensive range of services and accurate, reliable, timely data to drive decision-making at every stage of the oncology drug development process, we utilize an array of advanced technologies and platforms.
We apply these technologies strategically and in a tailored fashion to meet the unique assay demands of complex oncology projects. The platforms we most commonly use in oncology-related studies at BioAgilytix include:
See why BioAgilytix is experienced in developing bioanalytical strategies to investigate the mechanisms of oncolytic virus immunotherapies, from their antitumor properties to immune interaction effects.
The development of novel oncological therapeutic tools requires specific and sensitive bioanalytical methods and customized assays, and our veteran scientists have the expertise it takes to advance them. In fact, our scientific team has published more than 100 articles in the oncology arena, showing our commitment to this this area of study.
Trial success also hinges just as much upon researchers and scientists anticipating the addressing every scientific complexity at every stage of the drug development process. We understand that your potentially life-saving cancer therapy is no place for compromises, and work as a partner and true extension of your team to provide thorough expertise in oncology-related bioanalytical research, with the relevant services, technological tools, and techniques you need to make needed advancements for the patients you serve.
If you have a project related to oncology research and development, and would like to learn how BioAgilytix will work to effectively progress it, please speak to our scientific team today.
